Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target

Author(s): Jiayin Yang, Xiaohong Liao, Jerry Yu, Ping Zhou*

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 19 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


CD73, also known as ecto-5’-nucleotidase (eN, NT5E, EC3.13.5), is the ratelimiting enzyme for adenosine generation and is expressed on multiple cells. Its expression is significantly influenced by hypoxia and inflammatory factors. During inflammation, CD73 protects endothelial barrier function and inhibits leukocyte trafficking. CD73 also promotes M2 macrophages (anti-inflammatory phenotype). In addition, CD73 is expressed on Treg cells and mediates immune suppression through adenosine. CD73 serves as an essential regulator for the immunity and inflammation. Its expression is related to many diseases, such as autoimmune diseases, ischemia-reperfusion injuries, arterial calcifications, and atherosclerosis. CD73 is overexpressed in many cancers. Its expression is positively associated with tumor growth, metastasis, angiogenesis, poor prognosis and resistance to chemotherapy. Thus, CD73 may be used for prognostic indicator and therapeutic target in diseases such as cancers.

Keywords: CD73, ecto-5'-nucleotidase, cancer, immunity, inflammation, disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 30 May, 2018
Page: [2260 - 2271]
Pages: 12
DOI: 10.2174/0929867325666180117101114
Price: $65

Article Metrics

PDF: 114
HTML: 30
PRC: 1